Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen to Apply Its PGx Tech to Drug Candidate Licensed from Mitsubishi Pharma

NEW YORK, April 13 (GenomeWeb News) - Perlegen Sciences has licensed a prospective diabetes drug from Mitsubishi Pharma to commercialize it for specific patient groups, the companies said yesterday.

 

Perlegen plans to use its genotyping technology "to improve upon the demonstrated efficacy and safety profile of MCC-555, which has been tested in over 1,000 patients" with the aim to select patients most likely to benefit, according to a company statement.

 

Under the agreement, Perlegen has exclusive rights, except for in Asia, to develop and commercialize the compound. In exchange, Mitsubishi will receive an upfront payment, and is eligible for milestone payments. Mitsubishi will exclusively license, for sales of the drug in Asia, genetic markers that Perlegen intends to find. Both companies will receive royalties from drug sales in the territory of the other party.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.